Semaglutide vs Tirzepatide — Research Comparison
⚠ Research Use Only: All compounds supplied by Aarise Healthcare are strictly for laboratory research and scientific investigation. Not for human consumption, therapeutic use, or clinical application. Buyers must comply with all applicable local laws and regulations.
A research reference comparing Semaglutide and Tirzepatide — GLP-1 vs Dual GIP/GLP-1 agonist research comparison. This comparison is for scientific research reference only.
Side-by-Side Comparison
| Property | Semaglutide | Tirzepatide |
| CAS Number | 910463-68-6 | 2023788-19-2 |
| Category | GLP-1 Agonist | GLP-1 Agonist |
| Research Use | GLP-1 receptor agonism and metabolic research | dual GIP/GLP-1 incretin receptor research |
| Purity (Aarise) | 98%+ HPLC | 98%+ HPLC |
| Form | Lyophilised powder | Lyophilised powder |
Research Applications
Semaglutide is primarily studied for GLP-1 receptor agonism and metabolic research. Tirzepatide is studied for dual GIP/GLP-1 incretin receptor research. Researchers choose between these compounds based on their specific experimental model and endpoints.
Source Both Compounds from Aarise Healthcare
Aarise Healthcare supplies both Semaglutide and Tirzepatide at 98%+ purity from our WHO-GMP certified facility. Order both compounds together for consistent quality across your comparative research programme.
Request pricing for Semaglutide and Tirzepatide: Contact our research supply team with your quantity requirements. We respond within 24 hours.
